Compare Page
GHRP-6 vs Ipamorelin
Quick verdict: GHRP-6 and Ipamorelin are both growth hormone secretagogues that stimulate pulsatile GH release, but they differ markedly in selectivity and side-effect profiles. GHRP-6 is a potent but non-selective ghrelin-receptor agonist that also stimulates appetite, cortisol, and prolactin, while Ipamorelin is the most selective GH secretagogue studied, producing clean GH release without significant effects on other hormonal axes.
Read the full peptide profiles: GHRP-6 | Ipamorelin.
At a Glance: GHRP-6 vs Ipamorelin
Mechanism of Action
GHRP-6 and Ipamorelin both stimulate growth hormone release by binding to the growth hormone secretagogue receptor (GHS-R1a), the endogenous receptor for ghrelin. However, their binding profiles and downstream effects diverge considerably. GHRP-6 is a first-generation hexapeptide GH secretagogue that activates GHS-R1a potently but also triggers significant cross-reactivity — it stimulates ACTH and cortisol release, elevates prolactin, and robustly activates the appetite centres of the hypothalamus via the same ghrelin pathway. This makes GHRP-6 a powerful but “messy” secretagogue from a research perspective.
Ipamorelin represents a later-generation design specifically engineered for selectivity. While it acts on the same GHS-R1a receptor, dose-response studies have demonstrated that Ipamorelin stimulates GH release without concomitant increases in ACTH, cortisol, or prolactin at GH-effective doses. This selectivity has been attributed to its pentapeptide structure and distinct receptor-binding kinetics that preferentially activate the GH-releasing pathway while avoiding the broader hypothalamic-pituitary-adrenal (HPA) axis stimulation seen with GHRP-6. The result is a cleaner GH pulse that more closely mimics physiological release patterns.
Both peptides work synergistically with growth hormone releasing hormone (GHRH) — combining either GHRP-6 or Ipamorelin with a GHRH analog like CJC-1295 amplifies GH output beyond what either achieves alone. However, GHRP-6’s appetite-stimulating properties are an important consideration: in research models where appetite suppression is undesirable (such as cachexia or wasting studies), this may be advantageous, whereas in body composition research, the hunger drive can confound results. For related GH secretagogue comparisons, see GHRP-2 vs Ipamorelin and GHRP-2 vs GHRP-6.
Research Evidence
GHRP-6 is one of the most extensively studied GH secretagogues in the literature, with research spanning from the early 1980s through to the present. Its GH-releasing potency has been well-characterised in both animal models and human clinical studies. Bowers et al. published seminal work establishing GHRP-6 as a robust GH releaser, and subsequent studies confirmed its effects on appetite stimulation, cortisol release, and prolactin elevation. GHRP-6 has also been investigated for cardioprotective properties — animal studies have demonstrated cytoprotective effects in cardiac ischaemia-reperfusion models independent of its GH-releasing activity, suggesting additional receptor interactions.
Ipamorelin’s evidence base, while somewhat smaller in total volume, is notable for its clinical quality. The pivotal pharmacological characterisation by Raun et al. (1998) at Novo Nordisk demonstrated Ipamorelin’s exceptional selectivity — it was the first GH secretagogue shown to release GH with potency comparable to GHRP-6 while maintaining selectivity comparable to GHRH itself. Phase II clinical trials have investigated Ipamorelin for post-operative ileus recovery, where its GH-independent gut motility effects showed promise. This dual utility — GH release plus direct gut motility effects — represents a research advantage not shared by GHRP-6.
From an evidence-quality standpoint, both peptides benefit from human pharmacokinetic and pharmacodynamic data. GHRP-6 has broader historical depth; Ipamorelin has more targeted modern trial data. Neither peptide has received FDA approval, and both are classified as prohibited substances by WADA under the S2 category (peptide hormones, growth factors, related substances, and mimetics). For the broader GHRP family comparison, see GHRP-6 vs Hexarelin.
Key Differences
- Selectivity: Ipamorelin releases GH without affecting cortisol or prolactin levels; GHRP-6 elevates both alongside GH
- Appetite effects: GHRP-6 causes significant appetite stimulation via ghrelin-pathway activation; Ipamorelin has minimal appetite effects
- Half-life: Ipamorelin has a considerably longer half-life (~2 hours vs ~20–30 minutes), allowing less frequent dosing in research protocols
- GH pulse magnitude: At comparable doses, GHRP-6 may produce slightly higher peak GH levels, though the total AUC difference is modest
- Cardioprotection: GHRP-6 has documented cytoprotective effects in cardiac ischaemia models that appear independent of GH release; this has not been established for Ipamorelin
- Clinical development: Ipamorelin advanced further in modern clinical trials (Phase II for post-operative ileus); GHRP-6’s clinical data is primarily from academic pharmacological studies
Frequently Asked Questions
Does GHRP-6 release more growth hormone than Ipamorelin?
At equimolar doses, GHRP-6 typically produces a slightly higher peak GH concentration than Ipamorelin in comparative studies. However, the difference in total GH output (area under the curve) is modest. Ipamorelin’s advantage lies not in peak GH magnitude but in its selectivity — it achieves robust GH release without the cortisol, prolactin, and appetite side-effects that accompany GHRP-6 administration.
Why does GHRP-6 cause hunger but Ipamorelin does not?
Both peptides bind the ghrelin receptor (GHS-R1a), but GHRP-6 activates appetite-related signalling pathways in the hypothalamus more robustly than Ipamorelin. This is likely due to differences in receptor-binding kinetics and the degree to which each peptide mimics full ghrelin activity versus selectively activating the GH-releasing arm of the pathway. GHRP-6 is essentially a more complete ghrelin mimetic, while Ipamorelin is a biased agonist favouring GH release.
Can GHRP-6 or Ipamorelin be combined with CJC-1295?
In research settings, both peptides are frequently combined with CJC-1295 (a GHRH analog). The combination of a GHRP-class peptide with GHRH produces synergistic GH release — the two pathways (ghrelin receptor and GHRH receptor) converge on the somatotroph cell to amplify GH output beyond additive levels. See CJC-1295 vs Ipamorelin for more detail.
Which peptide is better for body composition research?
Ipamorelin is generally preferred in body composition research because its selectivity avoids cortisol elevation (which promotes fat storage and muscle catabolism) and appetite stimulation (which confounds dietary control). GHRP-6’s appetite-stimulating properties may be advantageous in wasting or cachexia research models where increasing caloric intake is a goal.
Does GHRP-6 raise cortisol levels significantly?
Yes — GHRP-6 reliably elevates ACTH and cortisol in dose-response studies, particularly at higher doses. This is an important consideration for research protocols sensitive to HPA axis perturbation. Ipamorelin, by contrast, does not produce statistically significant cortisol elevations at GH-effective doses, making it preferable when HPA axis neutrality is required.
Are GHRP-6 and Ipamorelin prohibited in sport?
Yes — both peptides are prohibited by the World Anti-Doping Agency (WADA) under category S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). They are prohibited at all times, both in-competition and out-of-competition. Detection methods for both peptides in urine have been developed and validated.
How does GHRP-6 compare to other GHRPs like GHRP-2 and Hexarelin?
GHRP-6 sits in the middle of the GHRP family for potency and selectivity. GHRP-2 is generally considered more potent per-milligram with somewhat less appetite stimulation. Hexarelin is the most potent GHRP but also has the strongest cortisol and prolactin effects. For detailed breakdowns, see GHRP-2 vs GHRP-6 and GHRP-6 vs Hexarelin.
References
- Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-1545. PMID: 6714155
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822
- Bowers CY. Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. 1998;54(12):1316-1329. PMID: 9893709
- Berlanga-Acosta J, Abreu-Cruz A, Herrera DG, et al. Synthetic growth hormone-releasing peptides (GHRPs): a historical appraisal of the evidence. J Endocrinol Invest. 2012;35(7):680-683. PMID: 22572768
- Hansen TK, Dall R, Hosoda H, et al. Weight loss increases circulating levels of ghrelin in human obesity. Clin Endocrinol (Oxf). 2002;56(2):203-206. PMID: 11874411
- Greenwood-Van Meerveld B, Tyler K, Mohammadi E, et al. Ipamorelin, a ghrelin mimetic, accelerates gastric emptying and improves gastrointestinal transit in a rat model of postoperative ileus. Life Sci. 2012;90(13-14):522-527. PMID: 22365961
- Jiménez-Reina L, Cañete R, de la Torre MJ, Bernal G. Influence of chronic GHRP-6 administration on GH secretion and hypothalamic CRF and SS content. Life Sci. 2002;70(9):1097-1108. PMID: 11860158